Financial Analysis: Whitehawk Therapeutics (NASDAQ:WHWK) and Vincerx Pharma (NASDAQ:VINC)

Vincerx Pharma (NASDAQ:VINC) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, dividends, profitability, valuation and risk.

Profitability

This table compares Vincerx Pharma and Whitehawk Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-248.33%	-132.73%
Whitehawk Therapeutics	N/A	-68.32%	-63.21%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Vincerx Pharma and Whitehawk Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vincerx Pharma	0	0	0	0	0.00
Whitehawk Therapeutics	1	1	2	0	2.25

Whitehawk Therapeutics has a consensus price target of $6.50, suggesting a potential upside of 85.19%. Given Whitehawk Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Vincerx Pharma.

Insider and Institutional Ownership

44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are held by institutional investors. 15.6% of Vincerx Pharma shares are held by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Vincerx Pharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Whitehawk Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Valuation & Earnings

This table compares Vincerx Pharma and Whitehawk Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00
Whitehawk Therapeutics	$25.98 million	6.37	-$63.69 million	$0.14	25.07

Vincerx Pharma has higher earnings, but lower revenue than Whitehawk Therapeutics. Vincerx Pharma is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Whitehawk Therapeutics beats Vincerx Pharma on 10 of the 12 factors compared between the two stocks.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

About Whitehawk Therapeutics

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.